Boehringer Ingelheim has revealed sales of its bovine viral diarrhoea (BVD) vaccine in the UK have passed the 500,000 mark.
In the 18 months since it was launched on the UK market, Bovela has been used to protect more than half a million cattle.
With BVD back on the agenda following the launch of England’s voluntary BVD eradication scheme, Wales soon to launch its own scheme and the Scottish scheme making progress, the company expects high uptake of the vaccine to continue.
Boehringer business manager Robert Bakewell said: “There is no doubt the vaccine has found itself as a firm favourite with farmers and vets in a relatively short space of time.
“As a single-shot vaccine that can be used in cattle from three months old onwards, Bovela is unique in the market. Other vaccines require a two-dose primary course with annual boosters or, in some cases, six-monthly boosters.
“These factors, and the fact Bovela brings innovation and a new level of immunity in the form of a live double-deleted vaccine, make Bovela a dramatically different product to other vaccines on the market.”
In other European countries, while BVD eradication schemes have reduced the prevalence of the disease, eliminating the tail of residual infection is said to be key to a country successfully becoming free of the disease.
Mr Bakewell added: “Bovela can be used alongside these schemes to ensure once a herd is free of BVD, it keeps infection out.
“Additionally, while BVD type one is the most commonly found strain of the virus, BVD type two has caused issues in some countries with and without eradication schemes, such as the Netherlands, Belgium, Germany and Spain, with the added issue that the old vaccines only provide fetal protection against type one.”
BVD type two can be a more aggressive strain of the virus, causing high numbers of deaths in herds where it is diagnosed. Bovela is the only UK licensed vaccine to provide proven protection against both BVD type one and type two.
For more information, visit Boehringer Ingelheim’s website.